Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Metric	ABBVAbbVie	AMGNAmgen	GILDGilead Sciences
Snapshot
Price	$259.74	$438.77	$149.70
Market cap	$461.26B	$201.93B	$162.98B
Valuation
P/E	125.2x	30.6x	20x
Forward P/E	144.7x	23.3x	14.3x
Growth
Revenue growth	9.5%	9.1%	3.5%
EPS growth	-13.5%	31.3%	55.5%
Profitability
Net margin	5.8%	21.0%	31.0%
ROE	95.6%	89.4%	42.2%
Balance sheet & cash
Debt / equity	20.19x	6.31x	1.1x
Free cash flow yield	3.9%	6.0%	5.2%
Dividend yield	3.1%	2.9%	2.6%
Verdict
Investment rating	Weak· 31	Favorable· 62	Strong· 74

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

Year	ABBVtoday $260	AMGNtoday $439	GILDtoday $150
2027	$198.70 – $291.43+12% CAGR	$431.98 – $633.57+44% CAGR	$174.58 – $256.05+71% CAGR
2028	$202.68 – $297.26+7% CAGR	$567.06 – $831.69+38% CAGR	$271.45 – $398.12+63% CAGR
2029	$206.73 – $303.20+5% CAGR	$744.38 – $1,091.76+36% CAGR	$422.08 – $619.04+61% CAGR
2030	$210.86 – $309.27+4% CAGR	$977.15 – $1,433.15+34% CAGR	$656.29 – $962.55+59% CAGR
2031	$215.08 – $315.45+4% CAGR	$1,282.70 – $1,881.30+34% CAGR	$1,020.46 – $1,496.67+58% CAGR
5-yr CAGR	-3.7% – 4.0%	23.9% – 33.8%	46.8% – 58.5%